Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update

Charles River Laboratories International, Inc. (NYSE:CRL) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 2,000,000 shares, a decline of 7.4% from the January 15th total of 2,160,000 shares. Based on an average daily volume of 785,400 shares, the days-to-cover ratio is presently 2.5 days.

Institutional Investors Weigh In On Charles River Laboratories International

Institutional investors have recently modified their holdings of the business. Versant Capital Management Inc lifted its stake in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the period. Assetmark Inc. grew its position in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the period. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the last quarter. Optiver Holding B.V. bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at $37,000. Finally, GeoWealth Management LLC boosted its stake in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after buying an additional 190 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CRL has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Monday, February 3rd. Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. TD Cowen upped their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. The Goldman Sachs Group lowered their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Finally, UBS Group reaffirmed a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $197.64.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $154.63 on Wednesday. The company has a market cap of $7.91 billion, a price-to-earnings ratio of 19.35, a P/E/G ratio of 6.47 and a beta of 1.37. The business’s fifty day simple moving average is $174.59 and its two-hundred day simple moving average is $189.16. Charles River Laboratories International has a 12 month low of $150.79 and a 12 month high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).